Detection of T and B cells specific complement-fixing alloantibodies using flow cytometry: A diagnostic approach for a resource limited laboratory

• Published in: Asian journal of transfusion science Vol. 11; no. 2; pp. 171 - 179
• Main Authors: Jain, Dharmendra, Dorwal, Pranav, Pande, Amit, Tyagi, Neetu, Mehra, Simmi, Raina, Vimarsh
• Format: Journal Article
• Language: English
• Published: India Medknow Publications and Media Pvt. Ltd 01.07.2017; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Alloantibodies; Antibodies; Antigens; B cells; Biopsy; C4d; Cytotoxicity; Developing countries; flow crossmatch; Flow cytometry; HLA antigens; human leukocyte antigen; Immunoglobulins; LDCs; Medical diagnosis; Medical laboratories; Medicine; Original; Pathology; renal transplant; Transplants & implants; C4d; Alloantibodies; human leukocyte antigen; flow crossmatch; renal transplant
• ISSN: 0973-6247; 1998-3565
• DOI: 10.4103/0973-6247.214355

Various methods have been reported for the detection of antibodies in recipient sera, which can be human leukocyte antigens (HLAs) or non-HLA specific, complement- or noncomplement fixing, as well as donor T (HLA-Class-I) and/or B cell (HLA-Class-I and II) specific. These alloantibodies play a pivotal role in antibody-mediated renal transplantation rejection. Deposition of C4d in peritubular capillaries of a kidney biopsy is a marker of antibody-mediated rejection. The C4d flow-panel reactive antibodies (PRAs) are a screening method for HLA-specific and complement fixing antibodies. However, the method is limited by the lack of donor specificity. Here, we present a new and simple flow cytometric method referred to as C4d-flow cytometry crossmatch (C4d-FCXM) for the detection of donor-specific (T and/or B cell) and C4d-fixing alloantibodies. The method was applied in a series of clinical cases and judged to be useful. The method may limit unwanted deferral of the donor due to positivity in C4d Flow-PRA and/or FCXM and may be helpful in prediction of antibody mediated rejections. Furthermore, this method can provide information pretransplant in contrast to kidney biopsy and C4d evaluation done posttransplant. We postulate that this method incorporates most of the features of all the available modalities (i.e., National Institute of Health-complement dependent lymphocytotoxicity, FCXM, cytotoxic FCXM and C4d-flowPRA) yet cost-effective and best suited for resource-limited laboratory/ies which is a common scenario in developing countries.